Ascendis Pharma (ASND) announced it has submitted a marketing authorization application to the European Medicines Agency for TransCon CNP as a treatment for children with achondroplasia, a rare genetic condition that causes skeletal dysplasia and, for many affected individuals, significant health, physical functioning, and quality of life impacts. TransCon CNP is an investigational prodrug of C-type natriuretic peptide administered once weekly, designed for continuous inhibition of the overactive FGFR3 pathway in achondroplasia by providing continuous exposure of active CNP to receptors on tissues throughout the body, including growth plates and skeletal muscle.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma’s Yorvipath: A Competitive Edge in Hypoparathyroidism Treatment Drives Buy Recommendation
- Ascendis Pharma Closes Warrant Exercise Window, Boosts Share Capital
- Wedbush sees no threat to Ascendis’ Yorvipath from competitor data
- Ascendis Pharma’s Market Leadership and Growth Potential in Chronic Hypoparathyroidism
- Buy Rating for Ascendis Pharma Driven by Yorvipath’s Efficacy and Upcoming Regulatory Catalysts